Onconetix, Inc. will hold an annual meeting on September 5, 2024, to vote on issuing 269,672,900 shares of common stock upon conversion of Series B Preferred Stock, a $5 million private placement financing, and the conversion of Proteomedix AG stock options, which may trigger a change of control requiring compliance with Nasdaq listing criteria.